



Clinical and Electrodiagnostic Profile of Diabetic Neuropathy in a Tertiary Hospital in Punjab, India

Vishali Kotwal, Amit Thakur*

Abstract

Peripheral neuropathy is commonly seen in diabetic patients especially with uncontrolled sugar levels. Its symptoms vary according to the type of nerve fibers involved which range from pain and numbness to tingling, weakness and areflexia. This study was undertaken to study the clinical profile of peripheral neuropathy in diabetes mellitus and to correlate it with various parameters. In this study, total 50 patients were studied. The detailed clinical examination was done and various parameters were studied including nerve conduction study. The most frequent complaint in this study was tingling and numbness and the most frequent sign was loss of ankle jerk. The severity of peripheral neuropathy increased with age as well as duration of diabetes and blood sugar levels.

Key Words

Peripheral Neuropathy, Diabetic Neuropathy, Diabetes Mellitus

Introduction

Diabetic neuropathy is a frequent microvascular complication of diabetes mellitus which is seen eventually in 60-70% of all people with diabetes.(1,2). Peripheral neuropathy is commonly caused in diabetics by a chronically high blood sugar which is shunted to polyol pathway and converted to sorbitol and fructose both of which lead to reduced nerve myoinositol. Other factors in the pathogenesis of diabetic neuropathy are advanced glycation end products, oxidative stress, vascular factors, growth factors and immune mechanisms(2).It may be symptomatic or asymptomatic in some cases and the symptoms depend upon the type of nerve fibers involved i.e motor, sensory or autonomic and also on the pattern of damage which is either focal or diffuse. So, diabetic neuropathies can be classified as mononeuropathies and polyneuropathies.(2)The more common diffuse neuropathies include diabetic sensorimotor polyneuropathy and diabetic autonomic neuropathy, which usually have a chronic and progressive course.(1,2).Diabetic sensorimotor polyneuropathy is the

most common clinical subtype seen in clinical practice.(3) It is potentially the most debilitating because it is associated with pain, discomfort and disability and also many of the patients are often asymptomatic, placing them at high risk of developing foot complications.

It is seen that a combination of age at onset, duration of diabetes and HbA1C which represents chronic glycaemic exposure better predicts diabetic neuropathy and other complications rather than individual components.(4).Apart from glycaemic control, diabetic neuropathy is seen to be associated with other risk factors like height,(5) and potentially modifiable cardiovascular risk factors like raised triglycerides, BMI, smoking and hypertension.(6,7-13)

Chronic painful peripheral neuropathy is seen in 16% to 26% of diabetic patients (14,15) and is due to small fibre involvement(16).Though patients with painful diabetic neuropathy have more glycaemic excursions than those with painless neuropathy (17) and it is related to duration of diabetes but glycaemic control is not a predictor

From the Department of Medicine & Orthopedics*, GGS Medical College and Hospital, BFUHS, Faridkot, Punjab- India

Correspondence to : Dr. Vishali Kotwal, Assistant Professor, Department of Medicine, Government Medical College, Iammu, J&K- India



of painful neuropathy as opposed to insensate neuropathy. (18). Peripheral neuropathy especially painful neuropathy is also seen in patients with impaired glucose tolerance, pre-diabetes and metabolic syndrome and most of the idiopathic neuropathy is associated with impaired glucose tolerance (19,20) but neuropathy seen in impaired glucose tolerance is milder than seen in diabetes mellitus.(21) and studies have shown that a diet and exercise regime improves metabolic measures and small fibre function(19) Also, it has been seen that prevalence of neuropathy in patients with impaired glucose tolerance at 60 minutes is higher than in patients with impaired glucose tolerance at 120 minutes(22).

Material and Method

This study was conducted over a period of 8 months from January 2012 to August 2012 in the Post graduate Department of Medicine of Guru Govind Singh Medical College, Faridkot, Punjab. The Hospital Ethics Committee gave ethical approval for the study. A total of 50 patients of diabetes mellitus attending indoor and outdoor departments who were having diabetes of more than 6 months duration were recruited. A written consent was obtained from all the patients. The cases included patients of both sexes and different age groups ranging from 20-70 years. The patients with current foot ulcer at the time of study, past history of stroke, peripheral nerve or vascular disease, limb surgery, history of exposure to known neurotoxins e.g; alcohol intake, treatment for tuberculosis or cancer, leprosy, myelopathies or known organ failure (renal, hepatic, cardiac, respiratory) were excluded from the study. Hemoglobin estimation, TLC, differential count, Urine sugar and ketones, Kidney function tests and Liver function tests were done in all the patients. ECG was done as per needed. Peripheral neuropathy was diagnosed clinically by obtaining UKST score. The UKST score is a two-part diagnostic test comprising symptoms score (abnormal sensation, site of discomfort, time of worse symptoms, and alleviating factors) and signs or disability score (ankle reflex, pain sensation, vibration sense, and temperature perception). The symptom scores have a maximum of 9 points while the sign scores have a maximum of 10 points. Minimum acceptable criteria for diagnosis of Diabetic peripheral neuropathy are either moderate disability with or without symptoms or mild disability with moderate symptoms. The ankle reflex was examined using a flexible tendon hammer. Vibration perceptions threshold was tested by tuning fork (128Hz) on each medial malleolus. Pain sensation was tested by pinprick, touch sensation with wisp of cotton, temperature sensation by hot and

cold water, position sense and deep tendon reflexes were also tested conventionally. Peripheral neuropathy was detected by nerve conduction study also and the nerves tested were Median, Peroneal and Sural. The criteria for detection and grading of peripheral neuropathy as mild, moderate and severe by nerve conduction study included Velocity (ms) between 45-49 as mild, 40-45 as moderate and < 40 as severe for Median nerve, between 40-42 as mild, 36-40 as moderate and <36 as severe for peroneal nerve. Also Amplitude was recorded and values between 2-4(mv) were graded as mild, between 1-2 (mv) as moderate and <1mv as severe for median nerve and values between 1-2 mv was graded as mild, between 0.5-1 mv as moderate and 0.5mv as severe for peroneal nerve.

Results

A total of 50 cases of diabetes were studied. Majority of the cases were in the age group of 41-50 years (Table 1). Male to female ratio was 1.5:1. The incidence of peripheral neuropathy was 40% on clinical examination (Table 2) whereas it was 58% actually when nerve conduction study was done. (Table 3) Maximum incidence was recorded in the age group of 51-60 years (70%) (Table 3). Maximum incidence was noted with duration of diabetes more than 6 years (Table 4). Maximum incidence of peripheral neuropathy was noted in blood sugar $s>300\text{mg}\%$ (Table 5). Clinical symptoms of peripheral neuropathy were directly proportional to blood sugar levels. Commonest presentation of peripheral neuropathy was impaired ankle jerk seen in 36% cases followed by tingling and numbness (30%), impaired vibration (24%), impaired touch sensation (14%) and pain seen in 16% (Table 6). Also severity of peripheral neuropathy as assessed by UKST score or by nerve conduction study was directly proportional to the blood sugar levels (Table 9 & 10) as well as the duration of diabetes in both males as well as females (Table 7 & 8).

Discussion

In our study, incidence of peripheral neuropathy was found to be 40% on clinical examination and 58% on nerve conduction study. Out of 50 cases, 30 were males and 20 were females. The age of the patients varied from 20-70 years; maximum patients were in the age range of 41-60 years. This is similar to study done by Kasturi *et al* (3) who found that peripheral neuropathy was more in patients over 40 years of age and with disease duration of more than 2 years. Tesfaye found a prevalence of 28% in their study (5). Young MJ *et al* (8) found an overall prevalence of 28.5% and a prevalence of 32% in

**Table 1. Age and Sex Wise Distribution of Patients**

Age	Male	Female	Total
21-30	04	05	09
31-40	03	02	05
41-50	15	07	22
51-60	06	04	10
61-70	02	02	04

Table 2. Incidence of Peripheral Neuropathy in Symptomatic Patients

Age	Total	Male	Females	Total	%age
21-30	09	01	01	01	11.1
31-40	05	01	01	02	40
41-50	22	06	04	10	45.4
51-60	10	03	02	05	50
61 & above	04	01	01	02	50
Total	50	12	08	20	40

Table 3 Incidence of Peripheral Neuropathy by Nerve Conduction Study

Age (Yrs)	Total Cases	Total Neuropathies	Male	Female	%age
21-30	09	02	01	01	22.2
31-40	05	03	01	02	60
41-50	22	15	09	06	68
51-60	10	07	04	03	70
61-70	04	02	01	01	50
Total	50	29	16	13	58

Table 4. Correlation of Symptomatology of Peripheral Neuropathy with Duration of Diabetes

Duration of Diabetes (Yrs)	Total cases	Total cases of Neuropathy	Males with neuropathy	Females with neuropathy	%age
1	05	-	-	-	-
2	06	02	01	01	33.3
3	07	02	01	01	28.5
4	06	04	02	02	66.6
5	12	08	05	03	66.6
6	10	09	06	03	90
>6	04	04	03	01	100
	50	29	18	11	58

Table 5. Correlation of Symptomatic Peripheral Neuropathy with Blood Sugar Levels

Blood sugar mg% Random	Total cases	Total cases of neuropathies	Males	Females	%age
120-180	04	-	-	-	-
180-200	09	03	02	01	33.3
200-230	10	06	04	02	60
230-260	12	08	05	03	66.6
260-300	08	06	03	03	75
>300	07	06	04	02	85.7
	50	29	18	11	58

T2DM and 37% in T1DM while in the age group of 70-79 years, he found a prevalence of 44%.(8).Again, J.Cabezas found an overall prevalence of 25% and a

prevalence of 38% in the age group of 75-79 years and prevalence increased with age and duration of disease.(9). Karvested L *et al* found a prevalence of 25%(10). This

Table 6. Common Clinical Features and Signs in Diabetic Patients

Complaints	No. of cases	%age
Tingling & Numbness	15	30
Impaired vibration	12	24
Impaired ankle jerk	18	36
Impaired touch sensation	07	14
Pain	08	16

Table 7. Correlation of Duration of Diabetes Mellitus with Severity of Peripheral Neuropathy According to Clinical Features and signs in male patients

Duration	Mild	Moderate	Severe	Total
2	01	-	-	01
3	-	01	-	01
4	-	02	-	02
5	-	03	02	05
6	-	02	04	06
>6	-	-	03	03

Table 8. Correlation of Duration of Diabetes Mellitus with Severity of Peripheral Neuropathy According to Clinical Features and Signs in Female Patients

Years	Mild	Moderate	Severe	Total
2	01	-	-	01
3	-	01	-	01
4	-	01	01	02
5	-	01	02	03
6	-	01	02	03
>6	-	-	01	01

Table 9. Correlation of Blood Sugar Levels with Severity of Peripheral Neuropathy in Male Patients

Blood sugar (mg %) Random	Mild	Moderate	Severe	Total
180-200	01	01	-	02
200-230	-	02	02	04
230-260	-	03	02	05
260-300	-	02	01	03
>300	-	-	04	04

Table 10. Correlation of Blood Sugar levels with Severity of Peripheral Neuropathy in Female Patients

Blood sugar (mg%)(R)	Mild	Moderate	Severe	Total
180-200	01	-	-	01
200-230	-	02	-	02
230-260	-	01	02	03
260-300	-	01	02	03
>300	-	-	02	02

variability may be due to patient selection, higher age group, longer duration and severity of diabetes or better health care facilities and awareness in these countries.

Shaw *et al.* (11) found that overall prevalence in his study was 12.7% which is lowest of all studies, however risk factors were the same i.e duration of diabetes and age. The diabetic neuropathy was seen most commonly after 4th to 5th decade in our study with a prevalence of 22% in the age group of 21-30 years and 70 % in the age

group of 41-70 years .In most of the patients, duration of disease was over 4 years .

Partanen *et al* (12) demonstrated rising incidence of peripheral neuropathy with increase of blood sugar levels as seen in our study. Dutta *et al* (13) found a lower incidence of peripheral neuropathy with blood sugar level in lower range. Kasturi *et al* found a positive correlation between duration of diabetes mellitus and prevalence and severity of peripheral neuropathy. Our study showed that



severity of peripheral neuropathy increased with rising blood sugar levels and increased duration of diabetes. Thus our study matched very well with the previous studies.

Conclusion

In our study, the prevalence of peripheral neuropathy was recorded as 40% on clinical examination whereas on nerve conduction study, it was found to be 58%. The most frequent complaint was tingling and numbness and the most frequent sign was loss of ankle jerk. Prevalence as well as severity of peripheral neuropathy increased with age as well as with rising sugar levels.

Thus it is concluded that a strict blood sugar control should be maintained in diabetics to prevent and delay the onset of peripheral neuropathy and a careful screening of diabetic patients should be done on a regular basis to detect neuropathy.

Also, nerve conduction study has an important role in detecting mild to moderate form of peripheral neuropathy in diabetic patients which is missed on only clinical examination. So nerve conduction study should be done routinely in diabetic patients who have more than 2-3 years of diabetes especially in the middle age and elderly group of people so as to pick up peripheral neuropathy at the earliest and prevent the long term complications like diabetic foot and ulcers and reduce the morbidity and mortality among these patients.

References

1. Tesfaye S, Boulton AJM, Dyck PJ, *et al.* Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. *Diabetes Care* 2010;33(10): 2285-93
2. Boulton AJM. Diabetic somatic neuropathies. *Diabetes Care* 2004;27(6):1458-86
3. Kasthuri AS, Sofat MS, Kumar CN. Somatic Neuropathy in Diabetes Mellitus. *MJAFI* 2000; 56: 33-36.
4. Dyck PJ, Davies JL, Clark VM, *et al.* Modeling chronic glycaemic exposure variables as correlates and predictors of microvascular complications of diabetes. *Diabetes Care* 2006 Oct;29(10):2282-8.
5. Tesfaye S, Stevens LK, Stephenson JM, *et al.* Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the Eurodiab IDDM complication study. *Diabetologia* 1996; 39:1377-86
6. Tesfaye S, Chaturvedi N, Eaton SE, *et al.* Vascular risk factors and diabetic neuropathy. *N Engl J Med* 2005 27;352(4):341-50.
7. Elliott J, Tesfaye S, Chaturvedi N. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. *Diabetes Care* 2009;32(10)1896-1900
8. Young MJ, Boulton AJM, MacLeod AF, *et al.* A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. *Diabetologia* 1993;36:150-154
9. Cabezas J. The prevalence of clinical diabetic peripheral neuropathy in Spain. *Diabetologia* 1998;41(11)1263-69
10. Kärvestedt L, Mårtensson E, Grill V, *et al.* The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. *J Diabetes Complications* 2011;25(2):97-106.
11. Shaw JE, Hodge AM, de Coruten M, *et al.*; Diabetic peripheral neuropathy in Mauritius: Prevalence and risk factors. *Diabetes Res Clin Pract* 1998; 43(2): 131-139.
12. Partanen J, Niskanen L, Lehtinen J. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. *New Engl J Med* 1995; 333(2): 8994.
13. Dutta A, Naorem S, Singh TP, Wangjam K. Prevalence of peripheral neuropathy in newly diagnosed type 2 diabetics. *Int J Diab Dev Countries* 2005; 25: 30-33.
14. Daousi C1, MacFarlane IA, Woodward A. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. *Diabet Med* 2004;21(9):976-82.
15. Davies M, Brophy S, Williams R, *et al.* A Taylor The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. *Diabetes care* 2006;29(7):1518-22
16. Vlckova E, Moravcova J. Small fibre involvement in diabetic patients with neuropathic foot pain. **Diabetic Medicine** 2008; 25(6) 692-699
17. Oyibo S, Prasad YD, Jackson NJ, *et al.* The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. *Diabet Med* 2002; 19:870-873
18. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. *Diabetes Research and Clinical Practice* 2002;57(1):45-51
19. Gordon Smith A1, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. *J Neurol Sci* 2006 ;242(1-2):9-14.
20. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. *Muscle Nerve* 2001;24:1225-1228
21. Sumner CJ1, Sheth S, Griffin JW, *et al.* The spectrum of neuropathy in diabetes and impaired glucose tolerance. *Neurology* 2003 ;60(1):108-11.
22. Sahin M, Karatas M, Sahin M, *et al.* High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels. *Minerva Endocrinol* 2008;33(4):289-96.